Mural Oncology plc (NASDAQ:MURA) Short Interest Down 15.7% in October

Mural Oncology plc (NASDAQ:MURA) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 392,800 shares, a decline of 15.7% from the September 30th total of 465,800 shares. Currently, 2.5% of the shares of the stock are short sold. Based on an average daily volume of 94,200 shares, the short-interest ratio is currently 4.2 days.

Mural Oncology Stock Down 0.8 %

MURA traded down $0.03 during trading on Wednesday, reaching $3.56. The company’s stock had a trading volume of 45,489 shares, compared to its average volume of 184,902. The company has a market cap of $60.66 million and a price-to-earnings ratio of -0.34. The firm has a fifty day simple moving average of $3.33 and a two-hundred day simple moving average of $3.40. Mural Oncology has a 1 year low of $2.88 and a 1 year high of $17.00.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, topping analysts’ consensus estimates of ($1.90) by $0.04. As a group, equities analysts forecast that Mural Oncology will post -7.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MURA shares. Raymond James initiated coverage on Mural Oncology in a research report on Friday, October 4th. They issued a “strong-buy” rating and a $18.00 target price on the stock. HC Wainwright assumed coverage on Mural Oncology in a report on Thursday, October 17th. They issued a “buy” rating and a $18.00 price objective on the stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Harbor Capital Advisors Inc. purchased a new position in Mural Oncology in the second quarter worth approximately $115,000. Rhumbline Advisers purchased a new position in Mural Oncology in the second quarter valued at $34,000. BBR Partners LLC acquired a new position in Mural Oncology during the 2nd quarter worth $31,000. Acadian Asset Management LLC acquired a new stake in Mural Oncology in the 2nd quarter valued at about $998,000. Finally, Nicollet Investment Management Inc. acquired a new position in shares of Mural Oncology during the second quarter worth about $308,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.